• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Virtual Screening Opportunities in Drug Discovery in Europe Product Image

Virtual Screening Opportunities in Drug Discovery in Europe

  • Published: January 2007
  • Region: Europe
  • 85 Pages
  • Frost & Sullivan

This Frost & Sullivan research service titled Virtual Screening Opportunities in Drug Discovery in Europe provides an overview of in-silico solutions in drug discovery. The study offers a complete analysis of key market drivers, restraints and trends. It also includes strategic solutions that will enable vendors to gain advantage in the growing market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following regional markets: Germany, the United Kingdom, France, Spain, Italy and the rest of Europe.

- Executive Summary
-- Industry Snapshot
--- Executive Summary

- Exchange Rates and Glossary of Terms
-- Glossary and Exchange Rates
--- Glossary of Terms
--- Exchange Rates

- Industry Challenges
-- Industry Challenges
--- Industry Challenges

- Market Engineering Research of the Virtual Screening Markets in Europe
-- Forecasts for the Virtual Screening Markets in Europe
--- Introduction and Market Overview
--- Research Scope and Methodology
--- Market Engineering Measurements
--- Market Trends
--- Market Drivers
--- Greater Generation of Data Increases the Demand for Better Tools to Manage and Analyse the Data
--- The Need to Increase Drug Productivity
--- In-silico Solutions Increase Adoption and Return on Investment
--- Elimination of False Leads at the Early Stage Reduces Attrition Rates
--- Virtual Screening Demand is Driven by an Increase in Governmental R&D Spending
--- Increasing Trend Towards Dry Laboratory Techniques
--- Market Restraints
--- Lack of Consistent and Accurate Data can Restrain the Development to Build Better Models
--- Non-standard and Alternative Developing Technologies Hinder the Acquisition of High-quality, Reliable Data
--- A Conservative Attitude on New Technologies can Restrain Adoption
--- Increasing Use of In-House In-Silico Technologies may Minimise Drug Pipeline Trials
--- Total Revenue Forecasts
--- Technology Trends
--- End-user Trends
--- Geographical Trends
--- Competitive Structure
--- Future Opportunities

- Market Engineering Research of the Virtual Screening Markets in Germany
-- Forecasts for the Virtual Screening Markets in Germany
--- Market Engineering Measurements
--- Total Revenue Forecasts

- Market Engineering Research of the Virtual Screening Markets in the United Kingdom
-- Forecasts for the Virtual Screening Markets in the United Kingdom
--- Market Engineering Measurements
--- Total Revenue Forecasts

- Market Engineering Research of the Virtual Screening Markets in France
-- Forecasts for the Virtual Screening Markets in France
--- Market Engineering Measurements
--- Total Revenue Forecasts

- Market Engineering Research of the Virtual Screening Markets in Spain
-- Forecasts for the Virtual Screening Markets in Spain
--- Market Engineering Measurements
--- Total Revenue Forecasts

- Market Engineering Research of the Virtual Screening Markets in Italy
-- Forecasts for the Virtual Screening Markets in Italy
--- Market Engineering Measurements
--- Total Revenue Forecasts

- Market Engineering Research of the Virtual Screening Markets in the Rest-of-Europe
-- Forecasts for the Virtual Screening Markets in the Rest-of-Europe
--- Market Engineering Measurements
--- Total Revenue Forecasts

- Market Engineering Strategic Recommendations
-- Market Engineering Strategic Recommendations
--- Strategic Recommendations

- Decision Support Databases
-- Decision Support Databases
--- Decision Support Databases

- Database of Key Industry Participants
-- Key Industry Participants
--- List of Key Industry Participants

Need to Increase Drug Productivity Key Factor Influencing Adoption of Virtual Screening Solutions

Some of the key factors driving the expansion of virtual screening solutions in drug discovery in Europe include high throughput capabilities, larger libraries as a result of combinatorial chemistry and increased automation, which are enhancing cost-effectiveness, as well as improving drug attrition rates. This is leading to rapid innovation and product development, potentially raising the number of drug candidate approvals and enhancing the scope for an increased drug research and development (R&D) portfolio. These factors are expected to positively impact growth in the European drug discovery virtual screening market.

"The increasing economic pressure on the pharmaceutical industry to develop new drugs in a faster, efficient and more economic way than in the past has led to the development of a large number of new methods aimed at a more efficient and rapid lead structure discovery process," notes Frost & Sullivan Programme Leader, Dr. Amarpreet Dhiman. "Recent advances in combinatorial chemistry have made it possible for chemists to synthesise large libraries of compounds and high throughput screening (HTS) provides a considerable reduction in the time needed for the discovery of new molecules possessing biological activity for a certain target." The experimental efforts to carry out the biological screening of billions of compounds are still high and therefore, computational techniques and computer-aided drug design approaches have emerged as a promising tool to assist researchers in decisions regarding what to screen and synthesise.

High-quality, Reliable Accurate Data Crucial for Market Success

Most pharmaceutical companies now have access to models that seek to predict key properties of the chemical structures that their research teams plan to synthesise. These range from the simple application of the ubiquitous Lipinski’s rule of five, through to relatively sophisticated integration and scoring of a range of predictive models. Whilst the increasing use of predictive in-silico models is encouraging, it is fair to suggest that much research remains to be performed to demonstrate appropriate confidence in the output of currently developed models and to broaden the chemistry space covered.

Virtual screening suppliers face many challenges which include the inability to reach a wider scientific audience and the lack of common technology standards. While there is high demand for software tools, companies must develop and introduce the right kind of tools and solutions for their customers. The key to success is to demonstrate to customers the value that can be created by the proper implementation of in-silico solutions. In order to allow companies to witness the benefits of in-silico studies, data generated will need to be accurate and reliable. "Developing tools that facilitate data consolidation and information sharing is essential," explains Dr. Dhiman. "Systems can then be standardised, which allow solutions that integrate data from numerous tools and experiments."

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos